查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2019265

全球系統性肥大細胞疾病治療市場：依治療方法、疾病亞型、給藥途徑、藥物類別及地區進行分析－市場規模、產業趨勢、機會分析及2026年至2035年預測

Global Systemic Mastocytosis Treatment Market: Analysis By Treatment Approach, Disease Subtype, Route of Administration, Drug Class, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計未來十年，全球系統性肥大細胞增生症 (SM) 治療市場將保持穩定持續成長，這主要得益於疾病認知度的提高和治療方法的不斷創新。該市場預計在 2025 年達到約 5.6578 億美元，並預計在 2035 年達到約 13.3756 億美元。在 2026 年至 2035 年的預測期內，該市場將以約 9% 的複合年成長率 (CAGR) 成長，展現出強勁的上升趨勢，而這一趨勢的驅動力主要來自多種臨床和商業性因素。

推動這一成長的主要因素是標靶治療的持續進步，尤其是蛋白酪氨酸激酶抑制劑（TKIs）。這些藥物徹底改變了進行進行性系統性肥大細胞增生症患者的治療模式。 TKIs旨在特異性抑制KIT突變等分子促進因素，與傳統治療方法相比，能夠更精準、更有效地控制疾病。隨著研究的深入和更新、更具選擇性的TKIs的問世，晚期患者有望受益於更佳的治療效果和更廣泛的治療選擇。

顯著的市場趨勢

系統性肥大細胞增生症 (SM) 的治療市場高度集中，少數幾家主要企業佔據了大部分市場佔有率。其中，Blueprint Medicines 公司憑藉其在標靶治療的創新和強大的商業性實力，在市場中佔據主導地位。該公司的領先地位既體現在其對精準醫療的早期投入，也體現在其成功開發出直接針對疾病分子促進因素的治療方法。

儘管佔據主導地位，但多家主要競爭對手正積極爭奪市場佔有率，試圖重塑競爭格局。 Cogent Biosciences、諾華、AB Science 和 Decifera Pharmaceuticals 等公司正大力投資研發，以期將新型或改良治療方法推向市場。尤其是諾華，憑藉其傳統治療方法“lydapt”，在面臨來自更新、更具選擇性藥物的競爭日益激烈的情況下，仍然保持著市場地位。 「lydapt」在特定患者群體中仍然發揮著重要作用。

2026年，SM治療市場的競爭格局將如同高風險的西洋棋比賽，各公司將投入大量資金以求獲得競爭優勢。這不僅包括對臨床試驗和藥物研發的投資，還包括監管策略、市場進入以及與醫生合作等方面的努力。任何進展，例如新療法的推出、適應症的拓展或現有製劑的改進，都可能顯著改變市場格局。

  • 主要成長要素
  • 系統性肥大細胞增多症 (SM) 治療市場的成長受到更廣泛的人口趨勢的顯著影響，尤其是老年人口的快速成長。隨著預期壽命的延長和醫療保健體系的改善，老年人口的比例持續上升，慢性病和罕見疾病患者群體不斷擴大。預計到 2050 年，美國老年人口將達到約 8,200 萬，這反映了顯著的人口結構變化，預計將導致對醫療保健服務和專科治療的需求增加。
  • 新機會的趨勢
  • 系統性肥大細胞增生症 (SM) 治療領域的一個重大新趨勢是從骨髓切片檢查等侵入性診斷方法轉向高靈敏度的周邊血液檢測，例如液滴數位 PCR (ddPCR)。這項轉變顯著改善了患者識別流程，使診斷更加便捷、減輕了負擔，並被更廣泛地接受。雖然傳統的骨髓切片檢查準確，但它屬於侵入性檢查，通常伴隨疼痛，需要在專門的臨床環境中進行，這可能導致患者猶豫不決，從而延誤診斷。
  • 最佳化障礙
  • 儘管系統性肥大細胞增生症 (SM) 的治療市場正經歷強勁成長，但仍存在一些重大限制因素阻礙其廣泛應用。其中最主要的挑戰之一是治療帶來的沉重經濟負擔，尤其是蛋白酪氨酸激酶抑制劑 (TKI) 等先進治療方法。這些藥物每年的費用可能高達 44.5 萬美元左右，對患者、醫療系統和保險公司而言都是一筆不小的開銷。即使在醫保報銷系統完善的地區，如此高昂的費用也會限制患者獲得治療的機會，延誤治療啟動，甚至導致治療中斷，尤其對於那些保險覆蓋不足的患者而言更是如此。

目錄

第1章執行摘要：系統性肥大細胞疾病治療的全球市場

第2章：報告概述

  • 研究框架
    • 研究目標
    • 市場的定義
    • 市場區隔
  • 調查方法
    • 市場規模估算
    • 定性研究
    • 量化研究
    • 按地區分類的主要調查受訪者組成
    • 數據檢驗
    • 本研究的前提

第3章：系統性肥大細胞疾病治療全球市場概覽

  • 產業價值鏈分析
    • 原料
    • 藥物發現與研究
    • 藥物研發和臨床試驗
    • 製造業
    • 分銷管道
    • 醫療保健專業人員
    • 最終用戶
  • 產業展望
    • 系統性肥大細胞增生症的疾病概述和流行病學
    • 目前治療狀況（標靶治療與對症治療）
    • 精準醫療在罕見血液疾病中的作用
    • 開發平臺和臨床開發方案
    • 用於診斷和治療罕見疾病的醫療基礎設施
    • 孤兒藥認定方面的監理現況與趨勢
  • PESTLE分析
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場成長及前景
    • 市場獲利估算與預測（2020-2035）
  • 市場吸引力分析
    • 藥物類別
  • 可執行的見解（分析師建議）

第4章：競爭對手儀錶板

  • 市場集中度
  • 企業市場占有率分析（以金額為準，2025 年）
  • 競爭格局分析與基準測試

第5章：系統性肥大細胞疾病治療的全球市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測（2020-2035）
    • 藥物類別
      • 關鍵見解
        • 多激酶抑制劑
        • 抗組織胺藥
        • KIT抑制劑
        • 肥大細胞穩定劑
        • 皮質類固醇
        • 免疫調節藥物
        • 其他
    • 依疾病亞型
      • 關鍵見解
        • 低度系統性肥大細胞增生症
        • 隱匿性系統性肥大細胞增生症
        • 高惡性度系統性肥大細胞增生症
        • 系統性肥大細胞增多症伴隨造血系統惡性腫瘤
        • 肥大細胞白血病
    • 依疾病亞型
      • 關鍵見解
        • 標靶治療
        • 症狀治療方法
        • 細胞減重療法
        • 聯合治療
    • 透過行政途徑
      • 關鍵見解
        • 口服
        • 注射藥物
        • 靜脈注射
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 韓國
          • 澳洲和紐西蘭
          • ASEAN
            • 印尼
            • 馬來西亞
            • 泰國
            • 新加坡
            • 其他東協國家
          • 其他亞太地區
        • 中東和非洲
          • 阿拉伯聯合大公國
          • 沙烏地阿拉伯
          • 南非
          • 其他中東和非洲
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地區

第6章：北美系統性肥大細胞疾病治療市場分析

第7章：歐洲系統性乳房疾病治療市場分析

第8章：亞太地區系統性肥大細胞增多症治療市場分析

第9章：中東和非洲系統性肥大細胞疾病治療市場分析

第10章：南美洲系統性乳房疾病治療市場分析

第11章：公司簡介

  • Sanofi SA
  • AdvaCare Pharma
  • Cogent Biosciences, Inc.
  • Dr Reddys Laboratories Ltd.
  • AB Science SA
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA03261743

The global systemic mastocytosis (SM) treatment market is poised for steady and sustained growth over the coming decade, reflecting both increasing disease recognition and ongoing therapeutic innovation. The market is estimated to be valued at approximately USD 565.78 million in 2025 and is projected to reach around USD 1,337.56 million by 2035. This expansion represents a compound annual growth rate (CAGR) of about 9% during the forecast period from 2026 to 2035, indicating a robust upward trajectory driven by multiple clinical and commercial factors.

A key contributor to this growth is the continued advancement of targeted therapies, particularly tyrosine kinase inhibitors (TKIs), which have transformed the treatment landscape for patients with advanced systemic mastocytosis. These therapies are designed to specifically inhibit molecular drivers such as KIT mutations, enabling more precise and effective disease control compared to traditional treatment approaches. As research progresses and newer, more selective TKIs are introduced, patients with advanced forms of the disease are expected to benefit from improved outcomes and expanded treatment options.

Noteworthy Market Developments

The systemic mastocytosis (SM) treatment market is characterized by a high level of consolidation, with a small number of key players controlling a significant share of the landscape. Among these, Blueprint Medicines stands out as the dominant force, largely due to its focused innovation in targeted therapies and its strong commercial presence. The company's leadership position reflects both early investment in precision medicine approaches and successful development of treatments that directly address the molecular drivers of the disease.

Despite this dominance, several major challengers are actively competing to capture market share and reshape the competitive dynamics. Companies such as Cogent Biosciences, Novartis, AB Science, and Deciphera Pharmaceuticals are all investing heavily in research and development to bring new or improved therapies to market. In particular, Novartis continues to defend its established position with Rydapt. This is a legacy treatment that still plays a role in certain patient segments despite increasing competition from newer, more selective agents.

By 2026, the competitive landscape of the SM treatment market can be likened to a high-stakes chess match, where each company strategically deploys substantial financial resources to gain an advantage. This includes not only investment in clinical trials and drug development but also efforts in regulatory strategy, market access, and physician engagement. Every move-whether launching a new therapy, expanding indications, or improving existing formulations-can significantly alter market positioning.

  • Core Growth Drivers
  • The growth of the systemic mastocytosis (SM) treatment market is strongly influenced by broader demographic trends, particularly the rapid expansion of the aging population. As life expectancy increases and healthcare systems improve, the proportion of older individuals continues to rise, creating a larger pool of patients susceptible to chronic and rare diseases. In the United States, the geriatric population is projected to reach approximately 82 million by 2050, reflecting a substantial demographic shift that is expected to place increased demand on healthcare services and specialized treatments.
  • Emerging Opportunity Trends
  • A major emerging trend in the systemic mastocytosis (SM) treatment landscape has been the shift from invasive diagnostic procedures, such as bone marrow biopsies, to highly sensitive peripheral blood testing methods like droplet digital PCR (ddPCR). This transition has significantly improved the process of identifying patients with the disease, making diagnosis more accessible, less burdensome, and more widely accepted. Traditional bone marrow biopsies, while accurate, are invasive, often painful, and require specialized clinical settings, which can discourage patients from undergoing testing and delay diagnosis.
  • Barriers to Optimization
  • Despite the strong growth of the systemic mastocytosis (SM) treatment market, several significant restraints continue to limit its broader adoption. One of the most critical challenges is the severe financial burden associated with treatment, particularly with advanced therapies such as tyrosine kinase inhibitors (TKIs). These medications can cost approximately $445,000 per year, creating substantial economic strain for patients, healthcare systems, and insurers. Even in regions with strong reimbursement frameworks, such high costs can restrict accessibility, delay treatment initiation, or lead to discontinuation, especially for patients without adequate insurance coverage.

Detailed Market Segmentation

By drug class, Tyrosine Kinase Inhibitors (TKIs) hold a dominant position in the systemic mastocytosis (SM) treatment market, accounting for approximately 40% of the total share. This leadership is largely driven by their effectiveness in targeting the underlying molecular mechanisms of the disease, particularly mutations that drive abnormal mast cell growth and activation. As treatment approaches increasingly shift toward precision medicine, TKIs have become a cornerstone therapy due to their ability to inhibit disease-causing pathways.

By route of administration, oral therapies dominate the systemic mastocytosis (SM) treatment market, accounting for approximately 65% of the total share. This strong preference is closely linked to the chronic and lifelong nature of the disease, which requires continuous management rather than short-term intervention. Patients and healthcare providers generally favor treatment options that can be easily integrated into daily life, making oral medications a practical and convenient choice compared to hospital-based alternatives such as intravenous therapies.

By treatment approach, the targeted therapy segment represents the leading treatment approach in the systemic mastocytosis (SM) treatment market, accounting for approximately 41% of the total market share. This strong position is largely attributed to the growing shift toward precision medicine, where therapies are specifically designed to address the underlying molecular mechanisms of the disease rather than just managing symptoms. As healthcare systems increasingly prioritize personalized treatment strategies, targeted therapies have gained widespread acceptance among clinicians and researchers.

Segment Breakdown

By Drug Class

  • Multikinase inhibitors
  • Antihistamines
  • KIT inhibitors
  • Mast cell stabilizers
  • Corticosteroids
  • Immunomodulators
  • Others

By Disease Subtype

  • Indolent systemic mastocytosis
  • Smoldering systemic mastocytosis
  • Aggressive systemic mastocytosis
  • Systemic mastocytosis with associated hematologic neoplasm
  • Mast cell leukemia

By Treatment Approach

  • Targeted therapy
  • Symptomatic management therapy
  • Cytoreductive therapy
  • Combination therapy

By Route of Administration

  • Oral
  • Injectable
  • Intravenous

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a leading position in the systemic mastocytosis (SM) treatment market, accounting for 42.16% of the global share. This dominance reflects the region's well-established healthcare infrastructure, strong research ecosystem, and high level of awareness among clinicians and patients. Within North America, the United States plays a particularly significant role, contributing approximately 75% of the region's total market value.
  • A key factor supporting this growth is the impact of the FDA's Orphan Drug Act, which provides powerful incentives for companies developing therapies for rare conditions such as systemic mastocytosis. These incentives include seven years of market exclusivity upon approval, as well as tax credits and other financial benefits that reduce the cost burden of research and development. As a result, pharmaceutical companies are more willing to invest in innovative treatments, accelerating the pace of drug discovery and commercialization in this niche therapeutic area.
  • In addition to regulatory support, North America benefits from widespread adoption of advanced diagnostic technologies. Next-Generation Sequencing (NGS), now used in approximately 90% of oncology centers, has significantly improved the accuracy and efficiency of detecting genetic mutations associated with systemic mastocytosis, particularly mutations in the KIT gene. This high level of diagnostic precision enables earlier and more reliable identification of the disease, which in turn supports timely intervention and better patient outcomes.

Leading Market Participants

  • Sanofi SA
  • AdvaCare Pharma
  • Cogent Biosciences, Inc.
  • Dr Reddy's Laboratories Ltd.
  • AB Science SA
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Systemic Mastocytosis Treatment Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Systemic Mastocytosis Treatment Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Materials
    • 3.1.2. Drug Discovery & Research
    • 3.1.3. Drug Development & Clinical Trials
    • 3.1.4. Manufacturing
    • 3.1.5. Distribution Channels
    • 3.1.6. Healthcare Providers
    • 3.1.7. End User
  • 3.2. Industry Outlook
    • 3.2.1. Disease Landscape & Epidemiology of Systemic Mastocytosis
    • 3.2.2. Treatment Landscape (Targeted Therapy vs Symptomatic Management)
    • 3.2.3. Role of Precision Medicine in Rare Hematologic Disorders
    • 3.2.4. Drug Pipeline & Clinical Development Scenario
    • 3.2.5. Healthcare Infrastructure for Rare Disease Diagnosis & Treatment
    • 3.2.6. Regulatory & Orphan Drug Designation Landscape
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Drug Class
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Systemic Mastocytosis Treatment Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Increasing Adoption of Targeted Therapies for Treatment of Systemic Mastocytosis
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Drug Class
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Multikinase Inhibitors
        • 5.2.1.1.2. Antihistamines
        • 5.2.1.1.3. KIT Inhibitors
        • 5.2.1.1.4. Mast Cell Stabilizers
        • 5.2.1.1.5. Corticosteroids
        • 5.2.1.1.6. Immunomodulators
        • 5.2.1.1.7. Others
    • 5.2.2. By Disease Subtype
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Indolent Systemic Mastocytosis
        • 5.2.2.1.2. Smoldering Systemic Mastocytosis
        • 5.2.2.1.3. Aggressive Systemic Mastocytosis
        • 5.2.2.1.4. Systemic Mastocytosis with Associated Hematologic Neoplasm
        • 5.2.2.1.5. Mast Cell Leukemia
    • 5.2.3. By Treatment Approach
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Targeted Therapy
        • 5.2.3.1.2. Symptomatic Management Therapy
        • 5.2.3.1.3. Cytoreductive Therapy
        • 5.2.3.1.4. Combination Therapy
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Oral
        • 5.2.4.1.2. Injectable
        • 5.2.4.1.3. Intravenous
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Systemic Mastocytosis Treatment Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Drug Class
    • 6.2.2. By Disease Subtype
    • 6.2.3. By Treatment Approach
    • 6.2.4. By Route of Administration
    • 6.2.5. By Country

Chapter 7. Europe Systemic Mastocytosis Treatment Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Drug Class
    • 7.2.2. By Disease Subtype
    • 7.2.3. By Treatment Approach
    • 7.2.4. By Route of Administration
    • 7.2.5. By Country

Chapter 8. Asia Pacific Systemic Mastocytosis Treatment Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Drug Class
    • 8.2.2. By Disease Subtype
    • 8.2.3. By Treatment Approach
    • 8.2.4. By Route of Administration
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Systemic Mastocytosis Treatment Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Drug Class
    • 9.2.2. By Disease Subtype
    • 9.2.3. By Treatment Approach
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country

Chapter 10. South America Systemic Mastocytosis Treatment Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Drug Class
    • 10.2.2. By Disease Subtype
    • 10.2.3. By Treatment Approach
    • 10.2.4. By Route of Administration
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Sanofi SA
  • 11.2. AdvaCare Pharma
  • 11.3. Cogent Biosciences, Inc.
  • 11.4. Dr Reddys Laboratories Ltd.
  • 11.5. AB Science SA
  • 11.6. Glenmark Pharmaceuticals Ltd.
  • 11.7. Lupin Ltd.
  • 11.8. Pfizer Inc.
  • 11.9. Novartis AG
  • 11.10. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators